Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024)

Historic Non-Current Deferred Tax Liability for Sunshine Biopharma (SBFM) over the last 3 years, with Q4 2024 value amounting to $389513.0.

  • Sunshine Biopharma's Non-Current Deferred Tax Liability rose 7273.84% to $389513.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $389513.0, marking a year-over-year increase of 7273.84%. This contributed to the annual value of $389513.0 for FY2024, which is 7273.84% up from last year.
  • As of Q4 2024, Sunshine Biopharma's Non-Current Deferred Tax Liability stood at $389513.0, which was up 7273.84% from $48729.0 recorded in Q3 2024.
  • Sunshine Biopharma's 5-year Non-Current Deferred Tax Liability high stood at $389513.0 for Q4 2024, and its period low was $43032.0 during Q4 2022.
  • Its 3-year average for Non-Current Deferred Tax Liability is $103702.3, with a median of $48729.0 in 2024.
  • As far as peak fluctuations go, Sunshine Biopharma's Non-Current Deferred Tax Liability skyrocketed by 42401.24% in 2023, and later surged by 1323.9% in 2024.
  • Sunshine Biopharma's Non-Current Deferred Tax Liability (Quarter) stood at $43032.0 in 2022, then skyrocketed by 424.01% to $225493.0 in 2023, then soared by 72.74% to $389513.0 in 2024.
  • Its Non-Current Deferred Tax Liability stands at $389513.0 for Q4 2024, versus $48729.0 for Q3 2024 and $48729.0 for Q2 2024.